Skip to main content

FDA recall, , Moderate risk

Direct Rx Lidocaine Ointment

Lidocaine Ointment USP, 5.0 % 50g JAR may be weaker than labeled.

What happened

Direct Rx of Dawsonville, Georgia, voluntarily recalled Lidocaine Ointment USP, 5.0 % 50g JAR, Rx only, because the product is subpotent. The recall began on September 29, 2026, and was added to the FDA's Enforcement Report on October 29, 2026. The product was distributed nationwide within the United States.

The ointment was packaged and distributed by Direct Rx, Dawsonville, GA 30534. Customers were notified by letter. The recall was classified by the FDA on October 29, 2026, and in the FDA's weekly enforcement report on November 4, 2026.

What to do

The FDA notice gives no instructions for this recall. FDA's general advice for medicine recalls:

  1. Check the FDA or company notice for instructions specific to this product.
  2. Ask your pharmacist or doctor whether your lot is affected and what to do.

Is your jar affected?

Match the NDC and lot code listed under your product.

An NDC (National Drug Code) is usually printed on the drug's label.

  1. Lidocaine Ointment USP, 5.0 % 50g JAR

    NDC
    • 72189-0211-50
    Lot code
    • 03AP2511
    • 30AP2518
    • 18JU2519
    • 18JU2520

Recall details

Posted by FDA
Recall began
Status
Open
Sold in

Nationwide within the United States

Recalled by
Direct RxDawsonville, Georgia
Risk

Moderate risk

Taking it may cause short-term health problems, or ones that treatment can reverse. Serious harm is unlikely.

FDA Class II recall · How risk is rated

FDA event number
100229
Recall number
D-0107-2027
Quantity recalled
493 jars
Recall type
Voluntary: Firm initiated
How the company first told customers
Letter

All recalls from Direct Rx

Timeline

FDA's Enforcement Report is its public list of recalls; FDA posts a recall by adding it there.

  1. Direct Rx began the recall

  2. FDA posted the recall to its Enforcement Report and rated it Class II (moderate risk)

  3. Added to Recall Canary

  4. Summary updated

Summary by Recall Canary, written with AI · summary updated Oct 31, 2026 · primary source: U.S. Food and Drug Administration (opens in a new tab)